C5 and atypical hemolytic-uremic syndrome: The C5-specific mAb eculizumab (Legendre et al. 2013) has been used in kidney transplantation to prevent delayed graft function, in antibody-mediated rejection, atypical hemolytic uremic syndrome (aHUS) recurrence, and anti-phospholipid syndrome (Legendre et al. 2017).